SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense volatility as investors weigh stellar earnings and HBM demand against broader macroeconomic risks like escalating tensions in the Middle East. The community is deeply divided, with many labeling the sharp price decline as market manipulation while others treat the dip as a prime accumulation opportunity ahead of the stock's upcoming inclusion in the S&P 100.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is experiencing extreme volatility as investors weigh the company's strong revenue growth against a federal indictment involving co-founder Yih-Shyan Wally Liaw in an alleged AI chip smuggling scheme to China. While the company is not a named defendant and maintains it is cooperating with authorities, community sentiment remains sharply divided between those viewing the sell-off as a generational buying opportunity and others fearing long-term reputational damage and potential supply chain repercussions from Nvidia.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as traders debate the impact of high-stakes geopolitical brinkmanship in the Middle East, specifically revolving around threats to the Strait of Hormuz and potential infrastructure strikes. The community is actively divided, with many debating whether the ongoing volatility represents a genuine long-term supply shock or a series of tactical market manipulations driven by official rhetoric.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a massive leadership overhaul that saw the removal of CEO Peter Greenleaf and the appointment of Board Chair Kevin Tang as the new CEO. Investors are actively discussing this management shakeup as a long-awaited catalyst, with many speculating that the transition to Tangs team will finally pave the way for a potential acquisition or go-private deal.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

The community is actively debating the volatility of SCO as traders attempt to capitalize on shifting crude oil narratives amid geopolitical tensions in the Middle East. While many are focused on the potential for long-term gains if oil prices normalize, others are expressing frustration over the ETF's decay and its tendency to deviate from expected inverse performance during rapid market swings.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors react to bipartisan legislative efforts targeting sports betting on CFTC-regulated prediction markets, which analysts view as a potential competitive win for established operators like DraftKings. Community discussion is heavily focused on the company's 'Super App' strategy, debates over market share impacts from prediction market rivals, and ongoing frustration regarding management's selling activity.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is facing intense market volatility as investors weigh the company's recent earnings miss and debt concerns against speculation about a transformative POSCO partnership. The community is actively debating the reliability of leadership and the impact of steel tariffs, while some participants view the current price action as a strategic accumulation opportunity ahead of potential Q2 growth.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund has captured significant market attention following its recent NYSE debut, with investors actively debating its massive premium to net asset value versus the unique opportunity to gain liquid exposure to high-growth private AI companies like Anthropic, OpenAI, and SpaceX. While the community is split between bullish sentiment over the ticker's volatile price action and concerns regarding the restrictive six-month lock-up period for pre-IPO shareholders, the stock remains a high-conviction focal point for retail traders seeking exposure to venture-capital-backed tech.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPY is experiencing intense volatility and speculative trading as the market reacts to conflicting reports regarding potential peace negotiations between the U.S. and Iran. The community is sharply divided, with many traders questioning the credibility of leadership's optimistic statements while debating whether the price action represents a genuine market recovery or a temporary "pump and dump" driven by geopolitical noise.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing extreme volatility driven by a major price target upgrade from Bank of America and robust AI-related memory demand, while the community remains sharply divided between those betting on a massive short squeeze and others warning of an unsustainable bubble ready to burst. Investors are intensely focused on the stock's wide daily price swings and potential for a significant retracement, as participants debate whether recent momentum is fueled by institutional accumulation or speculative excess.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hudson Bay Capital Management LP Lowers Stake in Moderna, Inc. $MRNA

Hudson Bay Capital Management LP reduced its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 26.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,000 shares of the company's s...

Biotech Stocks Worth Watching - March 22nd

Danaher, Vertex Pharmaceuticals, and Moderna are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies whose primary business is biotechnology developing drugs, biologics, diagnostics, gene therapies, or other lifescience t...

Promising Biotech Stocks To Keep An Eye On - March 21st

Danaher, Vertex Pharmaceuticals, Moderna, United Therapeutics, ImmunityBio, argenex, and Medpace are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

In the latest trading session, Moderna (MRNA) closed at $51.38, marking a -1.89% move from the previous day.

Promising Biotech Stocks To Follow Today - March 20th

Danaher, Vertex Pharmaceuticals, and Moderna are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that...

Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?

VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.

<ul class="summary-bullets"><li>The therapy also gained momentum in the U.S. after NCCN added it as a treatment option for papillary bladder cancer patients unresponsive to BCG.</li><li>ImmunityBio has resubmitted its FDA application to expand Anktiva’s use, backed by clinical data showing strong cancer-free and bladder preservation rates.</li><li>The company is advancing Anktiva globally, with lung cancer trials underway and recent approvals in markets including Saudi Arabia.</li></ul>Shares of ImmunityBio, Inc. (IBRX) are set to snap a two-week losing streak after its cancer therapy Anktiva appeared on Macau’s latest drug list, adding to fresh momentum from a U.S. guideline expansion.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained over 5% this week, snapping a two-week losing streak that had erased nearly 15% of its value.<h2 class="st-heading-2">Anktiva Added To Macau Approved List</h2>Anktiva, which is available under the generic name Nogapendekin alfa, is an immunotherapy that helps activate the body’s immune system to better fight cancer. It is approved in the U.S. for use with standard BCG treatment in patients with a type of bladder cancer that no longer responds to BCG, including those with or without certain tumor growths.The Macau filing, with data as of March, lists Anktiva as a bladder cancer treatment, identifying Nogapendekin alfa as its active ingredient and noting it is given as an injection for bladder cancer. The list also includes therapies approved by regulators such as the U.S. Food and Drug Administration (FDA), China’s National Medical Products Administration (NMPA), and the European Medicines Agency (EMA).Anktiva’s inclusion places it alongside a roster of globally approved therapies from major drugmakers, including Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Janssen, Gilead Sciences, and Moderna, positioning it among established treatments across oncology and specialty care.<h2 class="st-heading-2">NCCN Expansion Adds To Momentum</h2>The Macau development comes in the same week that Anktiva was added to updated U.S. treatment guidelines. The National Comprehensive Cancer Network (NCCN) added Anktiva, used with BCG, as an “other recommended” option for patients with papillary bladder cancer that no longer responds to BCG and has not spread into muscle tissue.Earlier versions of the guidelines had included the therapy only for carcinoma in situ. The update expands the potential patient population under clinical guidance, even as the indication is not yet formally approved by the FDA.<h2 class="st-heading-2">Anktiva Seeks Label Expansion</h2>ImmunityBio is seeking to expand Anktiva’s label to include papillary bladder cancer and has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-declines-immunitybio-resubmits-anktiva-application-to-fda/cZdVj9URIIL">resubmitted</a> its supplemental biologics license application to the FDA after previously receiving a refusal-to-file letter. The filing includes additional data requested by the agency, including updated efficacy results and long-term follow-up.Clinical data from the Phase 2/3 Quilt 3.032 study showed that 58.2% of patients remained cancer-free at 12 months, while more than 80% avoided bladder removal surgery over a three-year follow-up period, according to the company.<h2 class="st-heading-2">Global Push For Anktiva Grows</h2>Beyond bladder cancer, ImmunityBio is advancing Anktiva in lung cancer, with two pivotal trials underway in first-line and second-line non-small cell lung cancer. The company said multiple countries have expressed interest in the program as it explores broader regulatory pathways.The therapy has already received authorizations in the U.K., Europe and Saudi Arabia. In January, Saudi regulators granted approvals covering both bladder cancer and metastatic non-small cell lung cancer, including use in combination with checkpoint inhibitors.ImmunityBio said product shipments are ready to begin for a Saudi launch of Anktiva for bladder cancer, following regulatory approvals, and that it has partnered with regional distributors to expand access across the Middle East and North Africa.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX slid to ‘bearish’ from the ‘extremely bullish’ zone over the past three months amid over a 300% surge in message volumes over the same period.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_ba9f17d55e.webp" alt="ibrx ss.png" width="963" height="143"><figcaption>IBRX sentiment and message volume as of March 20 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/cyberInvest/message/648013012">said</a>, “Macau - China. I’d say that’s kinda global. And unstoppable.”<stembedurl>https://stocktwits.com/cyberInvest/message/648013012</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/cyberInvest/message/648034961">said</a>, “with NMPA - Macau - China approval apparent, FDA needs to get with it. This level of disfunction is a national embarrassment. China approves before US for a US company??? This is like a Saturday Night Live skit.”<stembedurl>https://stocktwits.com/cyberInvest/message/648034961</stembedurl>IBRX stock has more than tripled over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List 

IBRX Stock - Anktiva, an immunotherapy for bladder cancer, was listed in Macau’s March filing alongside globally approved drugs from major pharma players.

Equity

Anktiva, an immunotherapy for bladder cancer, was listed in Macau’s March filing alongside globally approved drugs from major pharma players.

Pfizer vs Moderna: Which Pharma Stock Has More Upside?

Key PointsThe smaller, more volatile of these two companies has higher potential for significant gains...

Promising Biotech Stocks To Follow Now - March 19th

Danaher, Vertex Pharmaceuticals, argenex, Moderna, and United Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that develop, manufacture, or commercialize biological products and technologi...

Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRNA News

MRNAModerna Inc